Eugene

[email protected]

LATEST

Merck KGaA, Forty Seven Inc. in Ovarian Cancer Pact
By

By
Merck KGaA and Forty Seven Inc., a Menlo Park, California-headquartered clinical-stage company developing immuno-oncology treatments, have agreed to conduct a clinical trial combining Hu5F9-G4, a monoclonal antibody against the CD47…

BeiGene, Mirati in Immuno-Oncology Pact
By

By
BeiGene, a Beijing, China-headquartered clinical-stage biopharmaceutical company focused on immuno-oncology, and Mirati Therapeutics, a San Diego, California-headquartered clinical-stage oncology company, have signed an agreement for the development, manufacturing, and commercialization…

FDA Outlines Policy Priorities for 2018
By

By
The US Food and Drug Administration (FDA) has announced its 2018 Strategic Policy Roadmap, which highlights the agency’s priorities. Key items on the agency’s agenda are policies for: addressing the…

FDA Denies Citizen Petitions from Novo Nordisk, Allergan, and Amneal Pharmaceuticals
By

By

Senate Finance Committee Holds Hearing with HHS Secretary Nominee
By

By
The US Committee Senate on Finance held a hearing relating to the confirmation of President Donald Trump’s nominee for Secretary of the US Department of Health and Human Services (HHS),…

Friulchem Reports on Patent Ruling for Rifaximin
By

By
Friulchem S.p.A., a Vivaro, Italy-based contract development, and manufacturing organization for innovator and generic pharmaceutical products for human and veterinary use, reports on a recent ruling in Mexico regarding intellectual…

Sharp Completes Part of $23-Million Investment in Clinical Services Facility
By

By
Sharp Packaging Services, a part of UDG Healthcare plc, a company in contract packaging and clinical supply services, has completed the first phase in developing its new $23-million facility in…

PharmaIN, Shionogi & Co. Partner
By

By
PharmaIN Corporation, a Bothell, Washington-headquartered development-stage biopharmaceutical company, and Shionogi & Co., a pharmaceutical company, have signed an agreement with an exclusive two-year option to negotiate a license for a…

Sanofi, Alnylam Restructure RNAi Therapeutics Pact for Rare Diseases
By

By
Sanofi and Alnylam Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company focused on RNAi therapeutics, have announced a restructuring of their RNAi therapeutics alliance to streamline development and commercialization of certain products…

BI, BeiGene in Supply Pact
By

By
Boehringer Ingelheim (BI) and BeiGene, a Beijing, China-headquartered clinical-stage biopharmaceutical company focused on immuno-oncology, have signed a commercial supply agreement for tislelizumab, BeiGene’s investigational anti-PD-1 antibody. Tislelizumab will be manufactured…